Madrigal Pharmaceuticals Inc MDGL shares rose sharply on Monday after the company announced positive topline results from the pivotal Phase 3 MAESTRO-NASH (fatty liver disease) biopsy trial of resmetirom.
On CNBC’s "Options Action," Mike Khouw of Optimize Advisors said traders bought 559 January 110-calls at $12 per contract on Friday.
Don’t forget to check out our premarket coverage here.
Those calls traded at $120 per contract on Monday, which implies that traders saw a profit of around $5.5 million in just one trading day, Khouw mentioned.
MDGL Price Action: Shares of Madrigal Pharmaceuticals jumped 268.1% to close at $234.83 in the regular trading session on Monday, and rose another 0.5% in after-hours trading.
Check This Out: Over $13 Million Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
